4.41
price up icon1.85%   0.08
after-market Dopo l'orario di chiusura: 4.41
loading
Precedente Chiudi:
$4.33
Aprire:
$4.32
Volume 24 ore:
124.30K
Relative Volume:
0.63
Capitalizzazione di mercato:
$199.75M
Reddito:
$84.82M
Utile/perdita netta:
$-21.43M
Rapporto P/E:
-9.00
EPS:
-0.49
Flusso di cassa netto:
$-27.23M
1 W Prestazione:
+4.50%
1M Prestazione:
+0.00%
6M Prestazione:
-28.76%
1 anno Prestazione:
-63.73%
Intervallo 1D:
Value
$4.29
$4.45
Intervallo di 1 settimana:
Value
$4.20
$4.50
Portata 52W:
Value
$3.55
$16.11

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name
Nome
Y Mabs Therapeutics Inc
Name
Telefono
646-885-8505
Name
Indirizzo
202 CARNEGIE CENTER, PRINCETON, NY
Name
Dipendente
107
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-04
Name
Ultimi documenti SEC
Name
YMAB's Discussions on Twitter

Confronta YMAB con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
YMAB
Y Mabs Therapeutics Inc
4.41 191.15M 84.82M -21.43M -27.23M -0.49
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-22 Downgrade BofA Securities Neutral → Underperform
2024-11-18 Iniziato Oppenheimer Outperform
2024-08-16 Iniziato Cantor Fitzgerald Overweight
2024-06-28 Iniziato Truist Buy
2023-05-10 Aggiornamento Wedbush Neutral → Outperform
2023-04-03 Downgrade Guggenheim Buy → Neutral
2023-01-27 Downgrade Morgan Stanley Equal-Weight → Underweight
2023-01-05 Downgrade Cowen Outperform → Market Perform
2022-12-02 Downgrade BofA Securities Buy → Neutral
2022-10-31 Downgrade JP Morgan Neutral → Underweight
2022-10-31 Downgrade Wedbush Outperform → Neutral
2022-07-06 Ripresa Canaccord Genuity Buy
2022-06-24 Iniziato BMO Capital Markets Outperform
2022-02-03 Ripresa Guggenheim Buy
2021-11-19 Ripresa Morgan Stanley Equal-Weight
2021-11-16 Downgrade JP Morgan Overweight → Neutral
2021-05-07 Aggiornamento BofA Securities Neutral → Buy
2021-04-23 Ripresa Cowen Outperform
2021-03-22 Ripresa JP Morgan Overweight
2021-01-15 Downgrade BofA Securities Buy → Neutral
2020-11-09 Reiterato H.C. Wainwright Buy
2020-05-05 Iniziato Barclays Overweight
2020-05-01 Iniziato Janney Buy
2020-04-29 Iniziato Morgan Stanley Equal-Weight
2019-12-24 Iniziato JP Morgan Overweight
2019-11-20 Iniziato Guggenheim Buy
2019-09-04 Iniziato Wedbush Outperform
2019-04-01 Iniziato H.C. Wainwright Buy
2018-10-16 Iniziato BTIG Research Buy
2018-10-16 Iniziato BofA/Merrill Buy
Mostra tutto

Y Mabs Therapeutics Inc Borsa (YMAB) Ultime notizie

pulisher
03:52 AM

Is Y mAbs Therapeutics Inc. a good long term investmentMarket-beating performance - jammulinksnews.com

03:52 AM
pulisher
03:21 AM

What analysts say about Y mAbs Therapeutics Inc. stockConsistently high returns - Autocar Professional

03:21 AM
pulisher
01:31 AM

What drives Y mAbs Therapeutics Inc. stock priceAccelerated earnings growth - jammulinksnews.com

01:31 AM
pulisher
Jul 21, 2025

Y mAbs Therapeutics Inc. Stock Analysis and ForecastUnrivaled growth potential - Autocar Professional

Jul 21, 2025
pulisher
Jul 15, 2025

Y-Mabs Therapeutics Elects New Director at Annual Meeting - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

Y-mAbs Therapeutics announces results of annual shareholder meeting votes - Investing.com

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Y mAbs Therapeutics Inc. stock price move sharplySafe and Smart Investment Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Y mAbs Therapeutics Inc. stock attracts strong analyst attentionFree Risk Assessment Services - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

2nd Circ. Affirms Biotech Founder's Win In Trading Suit - Law360

Jul 14, 2025
pulisher
Jul 11, 2025

Transcript : Y-mAbs Therapeutics, Inc.Shareholder/Analyst Call - MarketScreener

Jul 11, 2025
pulisher
Jul 04, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Jul 04, 2025
pulisher
Jul 02, 2025

YMAB SEC FilingsY-Mabs Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 02, 2025
pulisher
Jun 25, 2025

Is Y-mAbs Therapeutics, Inc. overvalued or undervalued? - MarketsMojo

Jun 25, 2025
pulisher
Jun 15, 2025

Cantor Fitzgerald Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Overweight Recommendation - MSN

Jun 15, 2025
pulisher
Jun 14, 2025

Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles - Investing.com India

Jun 14, 2025
pulisher
Jun 13, 2025

Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 12, 2025

Millennium Management LLC Cuts Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 7,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 11, 2025
pulisher
Jun 09, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE - Defense World

Jun 08, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Has $38,000 Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Jane Street Group LLC - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Pending - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $179,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Deutsche Bank AG - Defense World

Jun 02, 2025
pulisher
May 30, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer - Defense World

May 30, 2025
pulisher
May 29, 2025

Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB) - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com

May 29, 2025
pulisher
May 29, 2025

Oppenheimer Adjusts Target Price for Y-mAbs Therapeutics (YMAB) - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Y-mAbs Therapeutics (YMAB) Target Price Lowered by Oppenheimer | YMAB Stock News - GuruFocus

May 29, 2025

Y Mabs Therapeutics Inc Azioni (YMAB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Capitalizzazione:     |  Volume (24 ore):